Verséa Ophthalmics Inc. is on a mission to transform and personalize clinical and therapeutic decisions in eye care. The company focuses on delivering an innovative Tear-based Point-of-Care (T-POC) quantitative testing platform and biologic solutions that optimize diagnosis, treatment, and management of various conditions, including ocular surface disease such as persistent epithelial defects , corneal dystrophies, and neurotropic keratitis as well as surgical conditions such as pterygium excision, conjunctivochalasis, and glaucoma tube shunts.
A newly launched product portfolio consists of a novel, Tear-based, Point-of-Care (T-POC) quantitative testing platform and complementary allograft therapeutics that will enhance clinical management and inform treatment decisions that ultimately lead to better patient care.
Verséa Ophthalmics is committed to supporting Eye Care Professionals with diagnosis, management, and treatment of patients with ocular surface diseases or requiring ocular surgery.
"Diagnosing dry eye and treating it effectively is one of the most important ways that you can improve patient satisfaction and grow your practice. If it's important to the patient, it should be important to all of us.
When you diagnose something preoperatively, it creates an expectation for the patient. When you diagnose the same disease postoperatively, it has become your complication."
-Eric Donnenfield, MD
4 Phases of Precision Eyecare Starts with T-POC Quantitative Tear Testing
Click to Enlarge Image
Learn More About T-POC Quantitative Testing Platform
Learn More about Biovance® 3L Ocular
Verséa is a registered trademark of Verséa Health, Inc.
©2024 Verséa Ophthalmics, Inc. All rights reserved.
If you would like to learn more about our Tear-based Point-of-Care (T-POC) Quantitative Testing Platform or Biovance 3L Ocular, please contact us at ophthalmics@versea.com
Subscribe to the Verséa Newsletter
Receive exclusive offers, discounts and latest industry insights, free of charge.
© 2024 Verséa Health, Inc. All rights reserved.